Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Shares Outstanding (Diluted Average) (2021 - 2023)

Cullinan Therapeutics has reported Shares Outstanding (Diluted Average) over the past 3 years, most recently at $42.7 million for Q3 2023.

  • Quarterly results put Shares Outstanding (Diluted Average) at $42.7 million for Q3 2023, down 8.26% from a year ago — trailing twelve months through Sep 2023 was $42.7 million (down 8.26% YoY), and the annual figure for FY2022 was $46.6 million, up 8.27%.
  • Shares Outstanding (Diluted Average) for Q3 2023 was $42.7 million at Cullinan Therapeutics, up from $40.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for CGEM hit a ceiling of $46.6 million in Q4 2022 and a floor of $40.0 million in Q2 2023.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $43.3 million (2021), compared with a mean of $43.7 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 8.61% in 2022 and later dropped 13.88% in 2023.
  • Cullinan Therapeutics' Shares Outstanding (Diluted Average) stood at $43.1 million in 2021, then increased by 8.27% to $46.6 million in 2022, then dropped by 8.37% to $42.7 million in 2023.
  • The last three reported values for Shares Outstanding (Diluted Average) were $42.7 million (Q3 2023), $40.0 million (Q2 2023), and $40.7 million (Q1 2023) per Business Quant data.